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The mechanisms regulating lineage potential during
early hematopoiesis were investigated. First, a cas-
cade of lineage-affiliated gene expression signatures,
primed in hematopoietic stem cells (HSCs) and dif-
ferentially propagated in lineage-restricted pro-
genitors, was identified. Lymphoid transcripts were
primed as early as the HSC, together with myeloid
and erythroid transcripts. Although this multi-
lineage priming was resolved upon subsequent
lineage restrictions, an unexpected cosegregation of
lymphoid and myeloid gene expression and potential
past a nominal myeloid restriction point was identi-
fied. Finally, we demonstrated that whereas the zinc
finger DNA-binding factor Ikaros was required for
induction of lymphoid lineage priming in the HSC,
it was also necessary for repression of genetic
programs compatible with self-renewal and multipo-
tency downstream of the HSC. Taken together, our
studies provide new insight into the priming and
restriction of lineage potentials during early hemato-
poiesis and identify Ikaros as a key bivalent regulator
of this process.
INTRODUCTION
The prospective isolation of hematopoietic stem cells (HSCs)
and lineage-restricted progenitors, based on differential expres-
sion of cell surface markers or with surrogate markers driven by
hematopoietic-specific regulatory cassettes, identifies rare cells
with defined lineage activities (Iwasaki and Akashi, 2007). These
have been used in inferring past and current models of hemato-
poietic lineage restrictions. The HSC compartment is operation-
ally defined within the LinSca-1hic-Kithi (LSK) population in the
bone marrow (Morrison and Weissman, 1994; Osawa et al.,
1996). The use of additional markers, including CD34 and the
tyrosine kinase receptor Flt3, further subdivides the LSK
compartment into long-term HSCs, short-term HSCs, and multi-
potent progenitors (MPPs) (Adolfsson et al., 2001; Christensen
and Weissman, 2001). A substantial fraction (1/3–1/4) of the
LSK cells consists of progenitors with strong lymphoid andmyeloid potential but with limited erythro-megakaryocyte poten-
tial. These progenitors, also referred to as lymphoid-primed mul-
tipotent progenitors (LMPPs), are identified with independent
approaches that subdivide the LSK population; i.e., by differen-
tial expression of Flt3 (Adolfsson et al., 2005), of an Ikaros
reporter (Yoshida et al., 2006), and of the adhesion molecule
VCAM1 (Lai and Kondo, 2006). Importantly, these studies,
together with earlier reports on fetal hematopoiesis (Katsura,
2002), provide evidence for an obligate lympho-myeloid stage
of differentiation as a key branch point that leads into the
lymphoid and myeloid pathways. An early lymphoid progenitor
(ELP)with strong lymphoid but reducedmyeloid potential, a likely
descendant of the LMPP, is also identified in low numbers within
the LSK population, with the use of aRag1-GFP knockin reporter
(Igarashi et al., 2002).
Downstream of LSK differentiation, within the LinSca-1lo
c-KitloIL-7Ra+ population, a common lymphoid progenitor (CLP)
with strong in vitro potential for B cell, T cell, and NK cell differ-
entiation is described (Kondo et al., 1997). Recent studies have
shown that some CLPs still maintain myeloid potential (Mansson
et al., 2008; Rumfelt et al., 2006). Lineage-restricted megakaryo-
erythrocyte progenitors (MEP; CD34FcRlo) and granulo-mono-
cyte progenitors (GMP; CD34+FcRhi) are identified within the
LinSca-1c-Kithi (LK) population (Akashi et al., 2000). A rare
progenitor is also reported here: the commonmyeloid progenitor
(CMP; CD34+FcRlo), with combined erythroid and myeloid
potential.
Studies that address the activation and restriction of lineage-
specific transcriptional programs are providing an alternative
view into the earliest stages of hematopoiesis. Multipotent
progenitors are reported to express few genes affiliated with
disparate differentiation programs prior to lineage restriction,
a process known as lineage priming (Hu et al., 1997). The low
coexpression of genes from disparate lineages is taken as
evidence of multilineage priming through chromatin accessi-
bility, a step considered to be key for the rapid induction of
lineage-specific gene expression programs upon selection of
the affiliated cell fate (Bernstein et al., 2006). Earlier reports on
lineage priming indicate that myeloid-specific and erythroid-
specific, but not lymphoid-specific, transcripts are coexpressed
in a single HSC (Hu et al., 1997;Miyamoto et al., 2002). Lymphoid
transcripts are detected only in lineage-restricted progenitors,
such as the CLP (Miyamoto et al., 2002). More recent studies
show that lymphoid transcriptional priming canoccur in a fractionImmunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc. 493
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Regulation of Lymphoid Potential from HSC to GMPof the earlier progenitor population, the LMPP, in combination
with myeloid-lineage transcripts (Mansson et al., 2007).
Nuclear regulators expressed in early progenitors may control
cell fate by modulating expression of lineage-specific genes,
either stochastically or in response to environmental cues
(Chang et al., 2008). The Kru¨ppel-type zinc finger DNA-binding
factor Ikaros is expressed in the HSC and is essential for normal
lymphocyte development, maturation, and homeostasis (Geor-
gopoulos, 2002). Mutations in Ikaros indicate that it is essential
for development of the lymphoid lineage and that its effects
are manifested before the emergence of lymphoid-restricted
progenitors such as the CLP and the proB cells (Allman et al.,
2003; Wang et al., 1996). More recent studies show that Ikaros
is not required for the initial segregation of the lympho-myeloid
restricted progenitor, the LMPP, from the HSC but is required
for the LMPP’s subsequent progression into the lymphoid
pathway (Yoshida et al., 2006). Ikaros and its family members
are thought to regulate the expression of lineage-specific genes
by guiding key epigenetic and transcriptional events and by thus
contributing to a state of multilineage epigenetic competence in
the HSC and its progeny (Georgopoulos, 2002; Kioussis and
Georgopoulos, 2007). This hypothesis is borne out in part by
biochemical studies that have shown a stable association of
Ikaros and its family members with the nucleosome remodeling
and deacetylase complex (NuRD) (Kim et al., 1999; O’Neill
et al., 2000; Sridharan and Smale, 2007) and in part by Ikaros’s
association with the chromatin of lineage-specific genes (Harker
et al., 2002; Naito et al., 2007; Williams et al., 2004).
Seeking to establish the mechanisms that underlie early
hematopoiesis, we examined an HSC-enriched population and
its early progeny for expression of lineage-affiliated transcrip-
tional programs, referred to as signatures. Through comparison
of HSC, LMPP, GMP, andMEP populations, signatures affiliated
with self-renewal and lineage restriction were deduced. Using
transcripts deduced from this analysis, we showed that in
contrast to previous reports, at the single-cell level, extensive
transcriptional priming for lymphoid genes was detected
together with stem cell- as well as myeloid- and erythroid-affili-
ated transcripts in the HSC. Unexpectedly, lymphoid transcrip-
tional priming was detected in the GMP, which also exhibited
latent potential for lymphoid differentiation. Ikaros was identified
as a regulator of multilineage priming that was responsible for
activation of lymphoid signatures in the HSC and for repression
of lineage-inappropriate signatures downstream of the HSC.
Thus, lymphoid-lineage priming is established in the HSC, main-
tained past myeloid restriction, and regulated by Ikaros.
RESULTS
Identification of a Cascade of Lineage-Affiliated
Signatures in Early Hematopoiesis
Given new insights into early hematopoietic progenitors and their
unexpected lineage affiliations, we examined their expression of
lineage-affiliated transcriptional programs. An Ikaros-based
GFP reporter that provides a clean separation of the HSC-
enriched population (LSK GFP/loFlt3/lo) from the LMPP (LSK
GFP+Flt3lo-hi) and the GMP (LK GFPhi) from the MEP (LK GFP)
was used for cell isolation and gene profiling (Figure 1A, as
well as Figure S1, available online) (Yoshida et al., 2006). The
494 Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc.population referred to as HSCs (LSK GFP/lo) in our studies
consists of 80% LT-HSCs and ST-HSCs defined by the LSK
Flt3 profile and of 20% MPPs defined by the LSK GFP/lo
Flt3lo profile (Figure S1B) (Christensen and Weissman, 2001).
Transcriptomes deduced from three independent sets of these
cell types were normalized and subjected to Pearson correlation
analysis (Figure 1A). A similarity order from HSC to LMPP to
GMP, with MEP being the most dissimilar, was established.
The normalized transcriptomes of HSC, LMPP, GMP, and MEP
were also subjected to K-means clustering, which revealed 49
clusters of affiliated genes that fit into nine major signatures,
shown in Figure 1 and Table 1. The expression of these nine
signatures was also examined in the more lymphoid-restricted
proB (Linc-Kit+CD19+) for further insight into their lineage affil-
iation (Figure 1B).
The first set of signatures was restricted within the HSC and
LMPP populations (Table 1, stem and s-mpp, and Figure 1).
The first signature (stem) was specifically expressed in the
HSC-enriched population. The stem signature contained previ-
ously defined regulators of self-renewal (Ivanova et al., 2002).
The second signature (s-mpp) was expressed in both the HSC-
enriched population and the LMPPs. It lacked any lineage affili-
ation and was associated with the high proliferative potential of
an MPP. The s-mpp signature provided molecular evidence for
the relative primitiveness of the LMPP within the early progenitor
hierarchy.
The second set of signatures was expressed in the HSC pop-
ulation and in some of its lineage-restricted progeny, revealing
priming of lineage-specific genes as early as the HSC. A major
signature shared by the HSC, LMPP, and GMP and downregu-
lated in the MEP was designated as stem-myelo-lymphoid
(Table 1, s-myly). This consisted of factors of bothmyeloid differ-
entiation, such as Mpo, Csf3r, Lmo1, Gfi1, and Cebpb, and
lymphoid differentiation, such as Dntt, sterile Igh transcripts,
Satb1, Sox4, Foxp1, Flt3, and Notch1. Notably, expression of
both of the lineage-affiliated legs of the s-myly signature was
maintained in the GMP and, to a certain extent, within the pro-
B cell population, in spite of nominal lineage restrictions. A
stem-erythroid signature shared only by the HSC and MEP
was also deduced (Table 1, s-ery). The s-ery signature contained
known erythroid-lineage-differentiation factors, such as Gata1,
Klf9, Eraf, Tgfbr3, and Gja1. Notably, there was no marked
s-my signature (expressed by HSC and GMP and not by
LMPP) or s-myery (expressed by HSC, GMP, and MEP and not
by LMPP), suggesting that within the HSC compartment,
myeloid gene expression was activated concomitantly with
lymphoid gene expression.
The next group of signatures contained the second and third
layers of lineage-specific transcriptional priming that occurred
downstream of the HSC compartment and underscores addi-
tional lineage restrictions. A restricted myelo-lymphoid (Table
1, r-myly) signature represented a second layer of myelo-
lymphoid-lineage transcriptional priming that was specifically
activated in the LMPP and GMP and consisted of prominent
lymphoid (Il7r, Irf8, Igh, sterile transcripts) and myeloid (Csf1r,
Ly6c, Ccr2) differentiation markers (Table 1, r-myly). The
lymphoid components, but very few of the myeloid components,
of this signature were still expressed in proB cells. The third layer
of lineage priming represents further restriction into erythroid,
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Regulation of Lymphoid Potential from HSC to GMPmyeloid, or lymphoid cell fate. The d-ery was numerically the
largest progenitor-restricted signature, the d-my the second
largest, and the d-ly the smallest (Table 1, d-ery, d-my, and
d-ly). The relatively small size of the d-ly signature deduced
from the LMPP was consistent with its limited lymphoid-
lineage-restricted nature. The LMPP, although strongly primed
for lymphoid differentiation, in its majority retained bipotentiality
for both lymphoid and myeloid differentiation (Adolfsson et al.,
2005; Lai and Kondo, 2006; Yoshida et al., 2006). Finally, a group
of genes shared by the GMP, MEP, and proB but not by the HSC
A
B
C
Figure 1. A Cascade of Lineage-Specific Transcriptional Signatures Primed in the HSC and Propagated into Lineage-Restricted Progeny
(A) An Ikaros-GFP reporter that displays a bimodal distribution in the LSK and LK compartments was used for isolation of HSC-enriched (Figure S1B), LMPP (LSK
GFP+), MEP (LK GFP), and GMP (LK GFPhi) populations for global gene profiling. The developmental relationship between progenitors used for this study is
indicated. Progenitor expression profiles were subjected to Pearson correlation analysis and to K means clustering that deduced nine differentially expressed
signatures (Table 1).
(B) Heat map of signature expression in HSC, LMPP, MEP, GMP, and ProB. Signature designation is provided on the right.
(C) The relative distribution of each signature in HSC-enriched, LMPP, GMP, and MEP populations is shown for each developmental stage.
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Regulation of Lymphoid Potential from HSC to GMPand LMPP underscored the lineage-restricted state of hemo-
lymphoid progenitors and was thus designated as a differentia-
tion signature (Table 1, diff).
By comparative bioinformatics analysis of progenitor-derived
transcriptomes, we deduced a cascade of lineage-affiliated
signatures that was activated within the HSC compartment
and was propagated in a differential manner in lineage-restricted
progenitors (Figure 1C). Importantly, early lineage transcriptional
priming included not only erythroid- and myeloid- but also
lymphoid-affiliated transcripts. Thus, lymphoid and myeloid
gene expression programs were activated concomitantly and
remained associated through several steps of lymphoid and
myeloid differentiation, whereas erythroid-lineage restriction
involved the rapid elimination of opposing genetic programs.
Priming of Lymphoid, Erythroid, and Myeloid Gene
Expression in the HSC
Whereas coactivation of myeloid- and erythroid-affiliated genes
has been previously shown in HSC and MPP, activation of
a lymphoid gene expression program is thought to occur much
later in lymphoid-restricted or in lymphoid-primed progenitors
(Mansson et al., 2007; Miyamoto et al., 2002). Nonetheless, the
global cascade of lineage-affiliated signatures deduced from
our studies (Figure 1) indicated that lymphoid transcriptional
priming was active even earlier in multipotent progenitors and
possibly in HSC. To further explore these findings obtained at
the population level, we subjected single cells from the HSC-
enriched population (LSK GFP/lo) to multiplex RT-PCR analysis
for both HSC- and lineage-affiliated transcripts (Figure 2). Tran-
scripts that belonged to the first layer of lineage-affiliated signa-
tures were chosen for this study. Gata1, Klf1, and Tgfbr3 were
chosen from s-ery as representative of early erythroid transcrip-
tional priming. The myeloid—Mpo, Csf3r—and the lymphoid—
Dntt, Igh6, Lck, m0—components of the s-myly signature were
chosen as representative of early myeloid and lymphoid priming,
respectively. Mamdc2, Procr, and Mpl deduced from the stem
signature were used for identifying the cells that expressed
HSC-affiliated transcripts. These three transcripts were previ-
ously shown to be correlated with the HSC’s long-term reconsti-
tutionpotential (Balazs et al., 2006; Ivanova et al., 2002; Yoshi-
hara et al., 2007). The expression of selected genes was first
confirmed by real-time RT-PCR analysis in bulk progenitor pop-
ulations (Figure S2). cDNAs generated from single cells (n = 239)
were used inmultiplex RT-PCR reactions. An example of primary
data obtained from multiplex RT-PCR of single progenitors and
individual frequencies of transcripts within each population are
provided in Figure S3.
Sixty percent of the cells in the HSC-enriched population
expressed genes affiliated with self-renewal and were thus clas-
sified as HSC (Figure 2B and Figure S3, HSC). This number was
lower than the number of cells (80%) in this population with an
ST- and LT-HSC surface phenotype (LSK GFP/loFlt3,
Figure S1B). Lymphoid transcripts were detected in 29% of
these HSCs, erythroid transcripts in 24%, and myeloid tran-
scripts in 39% (Figure 2B). Lineage transcripts were also de-
tected in cells that are within the HSC-enriched population and
did not express self-renewal-affiliated transcripts and were
thus classified as MPP. Copriming of lymphoid with myeloid
(10%), lymphoid with erythroid (4%), lymphoid with erythroid
and myeloid (3%), and myeloid with erythroid (5%) transcripts
were detected in the HSC population. Thus, low levels of lineage
copriming were detected in both the HSC and the MPP subsets,
with no apparent bias (Figure 2C).
Thus, single-cell analysis revealed that lymphoid transcrip-
tional priming occurred in both HSCs and MPPs at a level that
was comparable to that of other hematopoietic lineages. Impor-
tantly, copriming of lymphoid, erythroid, and myeloid transcripts
was detected at similar low frequencies in HSCs andMPPs, indi-
cating that this process is stochastic in nature. The extensive
coexpression of HSC- and lineage-affiliated genes in early
hematopoietic progenitors suggests that priming for lineage
differentiation can occur concomitantly with a genetic program
that supports self-renewal.
Differential Resolution of Multilineage Priming
in Erythroid Versus Myeloid Progenitors
Next, we examined how multilineage priming detected in the
HSC and theMPPwas resolved in its lineage-restricted progeny,
Table 1. Lineage-Affiliated Signatures Deduced by K-Means Clustering of Progenitor Samples
Signature Definition Expression
Gene
Probe No.
stem contains self-renewing genes HSC (LT- + ST-) 483
s-mpp no significant expression of lineage-specific genes HSC/MPP, LMPP 315
s-ery erythroid lineage-specific genes primed in HSC. First wave of erythroid-lineage-specific
expression program
HSC/MPP, MEP 373
s-myly Lymphoid- and myeloid-lineage-specific genes primed in HSC. First wave of lymphoid- and
myeloid-lineage-specific expression program
HSC/MPP, LMPP,
GMP, ProB
1340
r-myly lymphoid and myeloid progenitors–primed lineage-specific genes. Second wave of lymphoid-
and myeloid-lineage-specific expression program
LMPP, GMP, ProB 92
diff no expression with lineage-specific genes. demarcating a progenitor-restricted state GMP, MEP, ProB 761
d-ery Erythroid-progenitor specific. Second wave of erythroid-lineage-specific expression program MEP 888
d-my Myeloid-progenitor specific. Third wave of myeloid-lineage program GMP 151
d-ly Lymphoid-progenitor specific. Third wave of lymphoid-lineage program LMPP, proB 23
Signature designation, definition, expression pattern, and gene probe set sizes are provided. Signature data are provided at http://www.massgeneral.
org/cbrc/research/researchlab.aspx?id=1070.
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Regulation of Lymphoid Potential from HSC to GMPthe MEP, LMPP, and GMP populations. The MEP (n = 78), unlike
the HSC, MPP, LMPP, and GMP populations, expressed only
erythroid transcripts (Figures 2A–2C). Additionally, HSC-affili-
ated transcripts were almost absent.
Downstream of the HSC and MPP, the LMPP, with very little
erythroid potential, is considered to be the first major restriction
point into the lymphoid and myeloid pathways. Consistent with
this notion, single-cell analysis of LMPPs (n = 211) revealed
that, in their vast majority, they expressed early lymphoid (93%)
and myeloid (73%) transcripts primed for expression in the
HSC (Figures 2A–2C, HSC versus LMPP). Coexpression of
lymphoid and myeloid transcripts was detected in the majority
of LMPPs (67%), whereas a substantial number of lymphoid-
only transcript-expressing cells (23%) were also detected
(Figures 2A–2C, LMPP). These numbers are comparable to the
previously reported frequency of myelo-lymphoid or lymphoid-
only progenitor activities within the LMPP (Adolfsson et al.,
2005; Yoshida et al., 2006). In contrast to the increase in lymphoid
and myeloid transcripts observed in the LMPP, expression of
HSC- and erythroid-affiliated transcripts was diminished.
Expression of erythroid transcripts was reduced from 24% in
the HSC to 2.7% in the LMPP (Figures 2A–2C), consistent with
the reduction in erythroid potential of the latter population and
a previous report (Mansson et al., 2007). HSC-affiliated tran-
scripts were also reduced from 60% in the HSC to 18% in the
LMPP, consistent with a further loss in self-renewal.
We also analyzed transcript expression in the myeloid-
restricted progenitor, the GMP, at the single-cell level (n =
120). GMP analysis demonstrated that 97% of these cells
expressed myeloid transcripts, compared to 73% of the LMPPs
(Figures 2A–2C, GMP). Surprisingly, lymphoid-lineage priming
was also widespread in this population; 93% of the cells
expressed some of the lymphoid transcripts detected in the
LMPPs (Figures 2A–2C). Nonetheless, expression of transcripts,
such as Dntt (LMPP: 64%, GMP: 20%) and Lck (LMPP: 32%,
GMP: 3%), was greatly reduced, whereas that of Igh6 (LMPP:
87%, GMP: 92%) and m0 (LMPP: 18%, GMP: 28%) was
increased (Figure S3, GMP). Thus, although specific compo-
nents of an early lymphoid-lineage programwere downregulated
in the GMP, others remained expressed at substantial levels. As
expected, the frequency of expression of myeloid transcripts—
Mpo (LMPP: 62%, GMP: 98%) and Csf3r (LMPP: 42%, GMP
52%)—was increased (Figure S3). As with the LMPP, HSC-
(7%) and erythroid-affiliated (5%) transcripts were diminished
in the GMP (Figures 2A–2C).
To obtain an independent measure of progenitor multipo-
tency, we also analyzed the single-cell type-specific transcript
data by Shannon information theory (see Experimental Proce-
dures). Based on transcript expression in single cells, this
method calculates the differentiation uncertainty for each
progenitor population in entropy bits (Figure 2D). The HSC pop-
ulation displayed the highest uncertainty, at 2.8 bits, the LMPP
population was next, with 1.4 bits, and the GMP population
followed, with 0.53 bits. Finally, MEP exhibited the least differen-
tiation uncertainty, at 0.29 bits. Thus, the derivation of lineage-
affiliated signatures in HSCs and early progeny, combined with
lineage-transcript analysis at the single-progenitor level, has
provided us with new, unexpected insights into lineage priming
and a measure of developmental plasticity.Latent Lymphoid Potential in the GMP
The unexpected expression of lymphoid-affiliated genes in the
GMP prompted us to further investigate its nature and potential
for differentiation. First, to understand how differences in
progenitor isolation protocols may contribute to differences in
progenitor composition, we compared our GMP isolation
protocol to one previously reported (Akashi et al., 2000)
(Figure S4A). Our protocol, which excludesMac-1+ cells, consis-
tently yielded a lower number of GMPs (2- to 4-fold) and, prob-
ably, a more primitive myeloid-progenitor population. The
presence of IL-7Ra+ cells within the GMP was found to be insuf-
ficiently low to explain its high frequency of lymphoid expression
(Figure S4B).
Next, we evaluated the GMP’s potential for lymphoid differen-
tiation, first under in vitro conditions. Limiting dilution analysis of
GMP and LMPPwas performed onOP9 stroma under conditions
that allow the generation of both B cells (B220+CD19+) and
myeloid cells (Mac1+Gr1+) and on OP9-DL1 stroma under condi-
tions that promote T cell differentiation (Figure 3A and Table S1).
Whereas LMPP exhibited similar potential for B cell, myeloid,
and T cell differentiation (frequencies of 1:7, 1:3, and 1:3),
GMP was distinguished by unexpected differences in lineage
potential (frequencies of B cell, 1:283; myeloid, 1:44; T cell,
1:24). The apparent reduction in GMP’s frequency for myeloid
differentiation as compared to LMPP (1: 44 versus 1:3) was prob-
ably due to a reduction in clonability and plating efficiency. The
greater reduction in theGMP’s frequency for B cell differentiation
(1:283 versus 1:7) indicated an additional loss in B cell potential
(Figure 3A). Notably, the reduction in GMP’s T cell frequency
(1:24 versus 1:3) was by far smaller and similar in range to the
reduction in myeloid frequency. The differentiation potential of
single GMPs was also investigated under T cell-differentiation
conditions (Figure S5A). Whereas all GMPs capable of clonal
expansion on OP9-DL1 gave rise to T cells, a fraction of these
gave rise to both T cells (DN3; Thy1+, CD44CD25+) andmyeloid
(Mac1+Gr1+) cells.
The GMP’s potential for differentiation was also evaluated
under in vivo differentiation conditions. The GMP differentiation
output was compared to that of the LMPP after direct placement
into a thymicmicroenvironment (Figure S5B). Six days after intra-
thymic injection of GMP (1000 LK GFPhi) or LMPP (25 LSK GFP+)
into sublethally irradiated recipients (GFP), donor-derived
myeloid cells (Mac1+GFP+) were detected in thymuses popu-
lated by either progenitor. At 21 days, donor-derived (GFP+)
double-positive (CD4+CD8+) thymocytes developed from GMP
or LMPP.
The ability of the GMP to migrate and differentiate into the
bone marrow and thymus was also tested relative to the LMPP
(Figure 3B). LMPP (2000 LSK GFP+) and GMP (GMPa: 7500 or
GMPb: 30,000 LK GFPhi) were injected intravenously into suble-
thally irradiated recipients. Total donor contribution, as well as
contributions into the myeloid, B cell, and T cell lineages, was
measured from 5 to 22 days after transplantation (Figure 3B).
Total donor contribution from either progenitor peaked at 2 wk
in the bone marrow and at 3 wk in the thymus. Donor-derived
myeloid differentiation peaked during the first week, whereas B
cell differentiation peaked during the second week (Figure 3B,
Mac1+ versus B220+). The kinetics of myeloid, B cell, and
T cell development were faster in GMP-derived cells comparedImmunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc. 497
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Figure 2. Multiplex Single-Cell Expression Analysis of Lineage-Affiliated Transcripts in HSC and Progeny
(A) Single cells from HSC, LMPP, GMP, andMEP populations were subjected to multiplex RT-PCR for Actb and lineage-affiliated transcripts (My:Mpo, Csf3r; Ly:
Dntt, Igh-6, Lck, and m0; Ery: Gata1, Klf1, and Tgfbr3; Stem:Mpl,Mamdc2, and Procr). Progenitors expressing at least one lineage-specific transcript are color
coded appropriately in each panel. Coexpression patterns of lineage transcripts are identified on the right side. The total number of cells from at least two sorts
used in these studies is indicated.498 Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc.
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Regulation of Lymphoid Potential from HSC to GMPto LMPP-derived cells consistent, with the GMP’s more
advanced stage in development. Whereas both the high and
lower dose of GMP gave donor-derived myeloid and B cell
contributions in the bone marrow, only the high GMP dose
contributed consistently to T cells in the thymus (with some
contribution detected by the low dose of GMP; data not shown).
Taken together, these studies demonstrate that the GMP not
only displays substantial expression for lymphoid genes but
also possesses marked potential for T cell differentiation.
Differences in the GMP’s potential for T cell differentiation re-
vealed by in vivo versus in vitro assays highlight this progeni-
tor’s normal homing to the bone marrow versus an intrinsic
capacity for T cell differentiation when provided with appropriate
signals.
Lymphoid-Lineage Transcriptional Priming
Is Dependent on Ikaros
Wehavepreviously shown that theLMPP’sdifferentiation into the
lymphoid branch of the lympho-myeloid pathway is uniquely
dependent on Ikaros (Yoshida et al., 2006). Given our new find-
ings of lymphoid-lineage transcriptional priming in the HSC, we
investigated the role of Ikaros in this process. HSC-enriched
and LMPP populations were isolated from Ikaros-null mice with
the use of the Ikaros GFP reporter (Yoshida et al., 2006) and sub-
jected toacomparativeglobal geneexpressionanalysiswith their
wild-type (WT) counterparts. Pearson analysis of mutant andWT
progenitor subsets revealed a strong correlation, supporting
similar cellular composition and lineage relationships (Figure 4A).
In the Ikaros-null HSC population, a similar number of upregu-
lated (276) and downregulated (280) gene probes were detected
(Figure S6A). As mutant HSC became restricted to the LMPP,
a 2-fold increase in the number of deregulated gene probes
(632 upregulated and 463 downregulated) was seen (Fig-
ure S6B), correlating with the previously reported increase in
endogenous Ikzf1 expression during this developmental
transition (Yoshida et al., 2006). We then examined how these
changes in gene expression were distributed within the
lineage-affiliated signatures deduced from the HSC and progeny
(Figures 4B and 4C). The majority of genes downregulated in the
Ikaros-null HSC and LMPP were distributed within the three
layers of the myelo-lymphoid signatures primed progressively
from the HSC to the LMPP and GMP (s-myly, r-myly, d-ly;
Figures 4A and 4B and Figure S6). The earliest primed s-myly
signature was enriched 4.5-fold among the downregulated
genes of the mutant HSC and LMPP and 3-fold in the mutant
GMP. The r-myly signature, representing the second layer of
myelo-lymphoid gene priming in the LMPP and GMP, exhibited
a 20-fold enrichment among the downregulated genes in the
mutant LMPP and a 6.7-fold enrichment in the mutant GMP.
Notably, most components of the late d-ly signature expressed
only in LMPP and proB were deregulated in the mutant LMPP,
exhibiting a 42.4-fold enrichment. Changes in gene expressionin the mutant HSC and LMPP were also subjected to an unbi-
ased hierarchical clustering across all WT and mutant progeni-
tors, providing us with an independent evaluation of their lineage
affiliation (Figures S6A and S6B).
The lymphoid leg of themyelo-lymphoid signatures was prom-
inently downregulated within the mutant progenitors (Figure 4A).
Among the first layer of lymphoid-affiliated genes downregulated
in the absence of Ikaros were Flt3, Notch1, Satb1, Btla, Dntt,
Igh-6, and Ltb (Figure 4C, s-myly). These include growth factor
receptors required for lymphocyte differentiation and a growth
factor important for the development and maintenance of
secondary lymphoid organs, which are absent in Ikaros-null
mice (Cupedo and Mebius, 2005; Radtke et al., 2004; Sitnicka
et al., 2003; Watanabe et al., 2003). The growth factor receptors
Il7r (r-myly), andCcr9 (d-ly), components of the second and third
layers of lymphoid-lineage priming, were also dependent on
Ikaros for expression (Figure 4C). The decrease in lymphoid-affil-
iated gene expression was also manifested in the GMP that nor-
mally maintains priming for some of these factors (Figure 4C).
Thus, Ikaros is required for the induction and propagation of
a cascade of lymphoid-lineage gene expression from the HSC
to its downstream lympho-myeloid-restricted progeny, the
LMPP and GMP. Several of the downregulated factors are
known effectors of lymphoid development. Others appear to
be novel and may provide us with new insight into the regulation
of this process.
Ikaros-Dependent Repression of Multilineage
Transcriptional Priming
Among the genes upregulated in early progenitors upon Ikaros
inactivation, a substantial number was affiliated with inappro-
priate cell fates (Figure 4 and Figure S6). Most strikingly, loss
of Ikaros resulted in the upregulation of numerous HSC-affiliated
genes. Among the genes that were upregulated in the LMPP and
GMP, a respective 10-fold and 7.5-fold enrichment was
observed in the HSC-affiliated signature (Figures 4A and 4B,
stem). HSC-affiliated transcripts with increased expression
included those of Procr, Mamdc2, Fgd5, Fscn1, Socs2, and
Socs3 and the receptor tyrosine kinases Tie1, Tek, and Mpl,
implicated in self-renewal (Figure 4C, stem). A 5- to 6-fold
enrichment of early primed erythroid factors (s-ery) was de-
tected, including Gja1, Tgfbr3, Il1rl1, Apoe, Gata1, and Klf9,
which are not normally expressed in the LMPP or GMP. Finally,
an enrichment (2- to 4.5-fold) of late myeloid genes, such as
Csf1r, Cebpd, and Id2, that are normally enriched in the GMP
was detected in the mutant HSC and LMPP, indicating their
premature induction (Figures 4A–4C, r-myly and d-my).
Thus, Ikaros, in addition to promoting priming and establish-
ment of lymphoid gene expression in the HSC and its early lym-
pho-myeloid progeny, is also involved in extinguishing the
expression of stem cell and erythroid genes and in preventing
the premature induction of late myeloid genes.(B and C) The percentage of overall lineage-affiliated transcript distribution (B) and the percentage of coexpression of lineage-affiliated transcripts (C) are
provided for cells in each progenitor. The percentage of progenitors that express HSC-affiliated genes is shown for both thewhole population and subsets primed
with lineage-specific genes. Mean ± SD on percentage distribution is shown.
(D) The single-cell expression data were analyzed by information theory (Shannon entropy) for provision of an independent measure of the differentiation uncer-
tainty (entropy value in bits) in each subset.Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc. 499
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Figure 3. Latent Lymphoid Potential in the GMP
(A) Limiting dilution analysis of GMP and LMPP for T cell-, B cell-, and myeloid-differentiation potential. Cells were sorted at the indicated doses and cocultured
with OP9-DL1 for 14–18 days and with OP9 for 8–11 days under conditions that promote T cell, B cell, and myeloid differentiation before analysis. Frequencies of
T cell and B cell differentiation were calculated with Po¨isson statistics. Combined data from four independent experiments are shown. R2 values are provided.
(B) 2000 LMPPs (open circle), 7500 GMPs (GMPa: grey diamond), or 30,000 GMPs (GMPb: black diamond) were intravenously injected into irradiated recipient
mice. Total and lineage-specific (Mac-1+, B220+, Thy1.2+) donor contribution (GFP+) was measured at days 5, 7, 13, and 22 after injection. For every time point,
2–4 mice per group were analyzed.
(C) Representative LMPP and GMP donor lineage contributions in the BM at day 7 and in the thymus at day 13 after transplantation are shown.Single-Cell Progenitor Analysis of Ikaros-Mediated
Changes in Lineage Priming
Loss of Ikaros in the early hematopoietic hierarchy deregulated
the activation, as well as the restriction, of lineage-specific
transcriptional programs. These apparent defects in lineage-
specific gene expression could in part reflect changes in the500 Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc.cellular makeup of mutant progenitors. Nevertheless, Pearson
correlation analysis indicated that the mutant HSC and mutant
LMPP populations were closely related to their WT counterparts
(Figure 4A). Ikaros-null HSC and LMPPwere further examined by
single-cell multiplex RT-PCR for expression of lineage-affiliated
transcripts (Figure 5). This line of study provided independent
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Regulation of Lymphoid Potential from HSC to GMPsupport that the cellular composition of these populations was
not significantly altered although priming of lymphoid transcripts
was reduced.
Of all lineage-affiliated transcripts, the frequency of lymphoid
transcripts detected was the most reduced in the Ikaros-null
HSC population (overall: WT, 28%; Ik-null, 15%; p < 0.1). Of
the lymphoid transcripts analyzed, Dntt was the most severely
affected (Figure S7). Smaller reductions in the frequency of
myeloid (overall: WT, 39%; Ik–null, 24%; p = 0.22) and erythroid
(overall: WT, 25%; Ik–null, 22%; p = 0.71) transcripts were
observed (Figure S7). Although some differences were noted in
lineage-transcript distribution and coexpression, their overall
pattern was not dissimilar to WT.
The transition from an HSC to a lympho-myeloid-restricted
LMPP is accompanied by an augmentation in the frequency of
myeloid and lymphoid transcripts. An increase in the frequency
of lymphoid transcripts was observed in the mutant LMPP
compared to the mutant HSC (Figure 5; overall: Ik–null LMPP,
56% versus Ik–null HSC, 15%; see also Figure S7). However,
this frequency was significantly lower compared to that
observed in the WT LMPP (Figure 5; overall: Ik–null LMPP,
52% versus WT LMPP, 93%, p = 0.01). A prominent decrease
in the frequency of certain lymphoid transcripts was again
observed in mutant LMPP as in mutant HSC. A decrease in the
frequency of detection of Dntt (WT, 66%; Ik–null, 8%) followed
by Igh-6 (WT, 87%; Ik–null, 48%), Lck (WT, 32%; Ik–null, 19%),
and m0 (WT, 19%; Ik–null, 15%) was evident (Figure 5B). The
frequency of myeloid-transcript expression in the mutant
LMPP (overall: Ik–null, 76%; WT, 73%; p = 0.55) was unchanged
compared to WT (Figures 5A and 5B). However, a significant
decrease in cells coexpressingmyeloid and lymphoid transcripts
(Ik–null, 35%; WT, 67%; p < 0.05) was detected (Figure 5C). An
increase in the frequency of HSC-affiliated (overall: Ik–null, 33%;
WT, 18%) and erythroid-affiliated (overall: Ik–null, 14%; WT,
2.7%) transcripts was observed in the mutant LMPP compared
to its WT counterpart (Figure 5B). Notably, Shannon entropy
analysis of the Ikaros-null HSC and LMPP single-cell RT-PCR
data provided similar entropy values for the two populations
(2.6 and 2.5 bits, respectively), suggesting that the mutant
LMPP retains a differentiation-uncertain HSC-like phenotype.
These studies establish a bivalent role for Ikaros in the tran-
scription of lineage-affiliated genetic programs downstream of
the HSC. On one hand, Ikaros is suppressing self-renewal- and
multipotency-affiliated genes, whereas on the other, it is acti-
vating lymphoid-differentiation-promoting genes.
Priming of the HSC’s Lymphoid-Lineage Potential
Is Dependent on Ikaros
Whereas B cell differentiation is not detected in Ikaros-null mice,
T cell differentiation takes place, albeit at a reduced frequency
(10%) compared toWT (Winandy et al., 1999). The T cell-differ-
entiation potential of HSCand LMPPwas compared in vitro in the
presence and absence of Ikaros (Figure 6A and Table S2). An
increase in T cell differentiation is normally detected from HSC
toLMPP (Figure 6A,WTHSC1:17 versusWTLMPP1:2), possibly
reflecting an increase in Notch1 expression (Figure 4C). A
comparison ofWT to Ikaros-null HSC revealed a50% reduction
in T cell activity in the mutant population (Figure 6A, 1:17 versus
1:31). Agreater reduction (10%) in Tcell potential wasobservedwhen Ikaros-null was compared to WT LMPP (Figure 6A, 1:19
versus 1:2). This is in line with their failure to induce Notch1
expression (Figure 4C) andwith thepreviously reported reduction
in thymic progenitors observed in Ikaros-null mice.
Thus, the priming and establishment of lymphoid-lineage
potential in the early hematopoietic hierarchy directly correlates
with the activation of a cascade of lymphoid gene expression.
The combination of these cellular and molecular events is
dependent on Ikaros.
Maintenance of Lymphoid Potential Is Dependent
on Ikaros
The role of Ikaros in activelymaintaining lymphoid potential in the
LMPP was further investigated. WT LMPPs were transduced
with lentiviruses that produce Ikaros-specific short hairpin
RNAs (shRNAs) and a GFP reporter for 48 hr. GFP-expressing
cells were sorted onto B cell- and T cell-differentiation cultures
and assayed under limiting dilution conditions (Figure 6B and
Table S3). Sorted cells were also analyzed for gene expression
(Figure 6C). Real-time RT-PCR analysis of sorted cells indicated
that Ikaros expression was decreased by 44%–45% in LMPP
transduced with IkshRNA (types 1 and 2) compared to cells
transduced with control shRNA. A change in expression of previ-
ously described Ikaros gene targets in the LMPP, such as Dntt,
Procr, Gja1 and Tgfbr3, was also observed.
After 8–10 days under B cell promoting culture conditions, the
progeny of transduced LMPP were analyzed for differentiation
into lymphoid (B220+CD19+) and myeloid (Mac1+Gr1+) cells.
B cell production was reduced in Ikaros shRNA-transduced
LMPP (frequencies: Ik shRNA1, 1:157; Ik shRNA2, 1:27)
compared to LMPP transducedwith control shRNA (1:11). Under
these culture conditions, Ikaros shRNA-transduced LMPP
produced myeloid cells at higher frequencies (Ik shRNA1,
1:2.5; Ik shRNA2, 1:4) compared to LMPP transduced with
control shRNA (1:68) (Table S3). A reduction in T cell potential
(Ik shRNA1, 1:9; Ik shRNA2, 1:10 versus ctl shRNA, 1:3) was
also observed in Ikaros shRNA-transduced LMPP grown under
T cell-differentiation conditions (Figure 6B).
Thus, Ikaros is required not only for establishment but also for
maintenance of lymphoid-lineage potential downstream of the
HSC.
DISCUSSION
We provided new insights into lineage transcriptional priming
and its regulation. A comparative analysis of global transcription
profiles, deduced fromHSC and progeny, established a cascade
of lineage-specific gene expression that underlies respective
progression into the erythroid or myeloid and lymphoid path-
ways. Lineage-affiliated transcripts deduced from this cascade
and examined for expression in a single HSC revealed priming
ofmyeloid, erythroid, and lymphoid transcripts at a similar robust
frequency (1/3). Coexpression of lymphoid, myeloid, and
erythroid transcripts, in different combinations, was detected
at lower frequencies, supporting a stochastic copriming of
opposing genetic programs in the HSC and MPP populations.
Subsequent lineage restrictions were demarcated by augmenta-
tion of HSC-primed, lineage-appropriate genetic programs and
by the rapid extinction of opposing genetic programs. ForImmunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc. 501
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Figure 4. Ikaros Effects on Lineage-Specific Signatures during Early Hematopoiesis
(A) Graphical representation of Pearson correlation analysis and heat map of signature expression in Ikaros-null versus WT progenitors. Signature designation
and Ikaros effects (down: green; up: red) are indicated on the right.502 Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc.
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Regulation of Lymphoid Potential from HSC to GMPexample, upon erythroid-lineage restriction, a concomitant
augmentation of erythroid transcripts primed in the HSC, as
well as extinction of transcripts affiliated with the lymphoid,
myeloid, and stem cell fates, was observed. Conversely, upon
HSC restriction into an LMPP, a concomitant establishment of
lymphoid and myeloid transcriptional programs and extinction
A
D
B
C
Figure 5. Multiplex Single-Cell Gene Expression Analysis of Ikaros-Null LMPP
(A) Single-cell analysis for lineage-affiliated transcripts was performed as described in Figure 2. Data frommutant LMPPs (n = 242) generated from two indepen-
dent sorts are shown.
(B) The percentage of overall lineage-transcript distribution, as well as of individual lineage-affiliated transcripts, is provided for WT and mutant cells. Asterisk
indicates p < 0.05.
(C) A comparison of lineage coexpression patterns betweenWT and KO LMPP is provided. The HSC-affiliated gene expression within each lineage coexpression
pattern is shown. Mean ± SD on percentage distribution is indicated.
(D) A model on multilineage transcriptional priming and its regulation by Ikaros. Priming of myeloid, erythroid, and lymphoid transcriptional programs occur at
a similar frequency (1/3) in the WT HSC. Subsequent lineage restrictions are demarcated by appropriate changes in lineage-specific transcripts. In the
HSC, Ikaros promotes priming of lymphoid genetic programs, whereas in lympho-myeloid-restricted progenitors, it represses expression of lineage-inappro-
priate transcripts, many of which are affiliated with self-renewal and multipotency.(B) Ratio of enrichment of gene signature sets with respect to Ikaros differentially regulated gene lists in mutant HSC, LMPP, and GMP as calculated by ratio-of-
ratios method. Downregulation of signature sets is not shown for progenitors where they are normally not expressed (undef).
(C) Effects of Ikaros deletion on select members of the stem, s-myly, s-ery, r-myly, d-my, and d-ly signatures. Genes exhibiting downregulation (green) and
upregulation (red) are shown. A heat map of the average expression level (base2 log-transformedmean centered;3.0 to +3.0) deduced from three independent
samples is shown.Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc. 503
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Figure 6. Ikaros Is Required for Priming, Augmentation, and Maintenance of Lymphoid Potential
(A) T cell-differentiation potential of HSC and LMPP fromWT and Ikaros-null mice as revealed by limiting dilution analysis. Cells were sorted at the indicated doses
and cocultured with OP9-DL1 for 14–21 days under lymphoid conditions. Frequencies of T cell differentiation were calculated with linear regression analysis of
five combined experiments (Table S2).
(B) The differentiation potential of LMPP transduced with lentiviruses expressing shRNAs for Ikzf1 (types 1 and 2) or control shRNA and cocultured with OP9 and
OP9-DL1. Data from one of two experiments are shown (Table S3).
(C) Real-time RT-PCR of lymphoid (Ikzf1, Dntt, IL7R), erythroid (Gja1, Tgfbr3), and stem (Procr) transcripts amplified from at least 5000 LMPPs harvested 48 hr
after lentiviral transduction. Data from two independent experiments, with mean ± SD, are shown.of erythroid and stem cell programs was detected. Unexpect-
edly, a marked expression of lymphoid genes was maintained
in the LMPP’s myeloid-restricted progeny, the GMP.
Recent models have suggested that lymphoid-lineage devel-
opment is initiated downstream of the HSC and after establish-
ment of a myeloid genetic program (Laiosa et al., 2006). This
assertion was partly based on the late evolutionary ontogeny
of lymphocytes and on recent evidence that lymphoid-lineage
priming is first detected in a fraction (30%) of the LMPP that
displays robust myeloid gene expression (Akashi et al., 2003;
Mansson et al., 2007). If myeloid gene expression positively rein-
forces myeloid differentiation, then this developmental outcome
should prevail most of the time. However, the balanced lympho-
myeloid differentiation potential reported for the LMPP does not
support this hypothesis (Mansson et al., 2007; Yoshida et al.,
2006). Studies that interrogated lymphoid priming in the HSC
and the LMPP did so with genes such as Il7r and Rag1 (Mansson
et al., 2007; Miyamoto et al., 2002). Although these genes are
readily expressed in committed lymphoid progenitors, such as
the CLP, they are not part of the earliest layer of lymphoid tran-
scription primed in the HSC (i.e., s-myly). Instead they are repre-
sentative of later layers of lymphoid transcription (i.e., r-myly and504 Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc.d-ly) described here. Thus, in contrast to previous reports, our
studies identify an early and extensive lymphoid genetic program
that is activated in the HSC, as well as reveal equal access to the
erythroid, lymphoid, and myeloid pathways at this early point of
hematopoiesis.
Multilineage priming detected in the HSC is resolved at subse-
quent lineage-restriction points. However, a continued associa-
tion of lymphoid and myeloid genetic programs and differentia-
tion potential was apparent not only in the LMPP but also,
unexpectedly, in its nominal myeloid-restricted progeny, the
GMP. The lack of erythroid potential and prominent myeloid
differentiation properties of this progenitor population were
previously described (Yoshida et al., 2006). Unexpectedly, our
current transcriptional analysis has demonstrated a widespread
expression of lymphoid genes throughout this population. The
implication that the myeloid-committed GMP retains a latent
lymphoid-lineage potential under both in vitro and in vivo differ-
entiation conditions was confirmed empirically here. In vivo
transplantation studies, although not quantitative, have demon-
strated that the GMP has latent potential for lymphoid differenti-
ation. The GMP or its progeny can migrate into the thymus and
undergo T cell differentiation at a low frequency. In sharp
Immunity
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Immunity 30, 493–507, April 17, 2009 ª2009 Elsevier Inc. 505contrast, in vitro, the GMP displays a robust potential for T cell,
but not for B cell, differentiation. Differences in the GMP’s poten-
tial for T cell differentiation revealed under in vitro versus in vivo
settings highlight the progenitor’s normal bone marrow homing
properties and an intrinsic capacity for T cell differentiation
when presented with appropriate signals. In this regard, it is
noteworthy that the Notch1 receptor, normally primed in the
HSC and upregulated in the LMPP, is still expressed in the
GMP and may be responsible for its T cell differentiation on
OP9-DL1 stroma. Taken together, our GMP studies and recent
reports on the ETP predict a similarity in the lineage-restriction
processes along the myeloid and T cell pathways (Bell and
Bhandoola, 2008; Wada et al., 2008). Both appear to involve
a rapid loss in B cell potential and a gradual loss in T cell or
myeloid potential, respectively.
The lymphoid potential of an HSC is augmented during restric-
tion to an LMPP, and this gain is dependent on Ikaros. In line with
this biological effect, Ikaros is responsible for the activation and
propagation of a cascade of lymphoid-lineage-promoting
genetic programs from the HSC to LMPP. Loss of Ikaros
uniquely reports both known regulators of early lymphopoiesis,
as well as some potentially novel regulators in this process.
The nuclear factors Sox4, Satb1, and FoxP1, previously impli-
cated in B cell and T cell development (Alvarez et al., 2000; Hu
et al., 2006; Schilham et al., 1996), are in the first line of regulators
downstream of Ikaros. These may work to augment expression
of lymphoid genes, as well as to repress competing genetic
programs. Signaling receptors, such as Flt3, IL-7Ra, and
Notch1, expressed in the HSC and LMPP and required for
lymphocyte development (Radtke et al., 1999; Sitnicka et al.,
2003), are also dependent on Ikaros for normal expression.
Increased expression of the negative signaling adaptors Socs2
and Socs3 (O’Sullivan et al., 2007) may provide additional inter-
ference to residual Flt3 or IL-7R signaling manifested in mutant
progenitors. Signaling molecules, such as Btla, Clnk, Pkib, and
CD52, shown to be important for functional responses of mature
lymphocytes (Greenwald et al., 2005; Kumar and Walsh, 2002;
Watanabe et al., 2003; Wu and Koretzky, 2004), are also
expressed in the LMPP, and their dependence on Ikaros
suggests that thesemay also contribute to early lymphoid devel-
opment. CCR9 expression in the LMPP supports progenitor
migration into the thymus (Benz and Bleul, 2005; Uehara et al.,
2002), and its loss in the mutant progenitors may explain the
reduced number of thymic progenitors reported in Ikaros-null
mice (Winandy et al., 1999). Finally, lack of lymph node struc-
tures in Ikaros-null mice (Wang et al., 1996) correlates with the
loss of Ltb expression required for lymph node structure devel-
opment (Cupedo and Mebius, 2005).
Loss of nuclear factors and signaling pathways that promote
lymphocyte differentiation from the LMPP is expected to unbal-
ance the lympho-myeloid genetic network operating in this
progenitor that controls its lymphoid versus myeloid output. A
premature augmentation in the expression of myeloid factors,
such as Csf1r, Csf2r, C/EBPa, b, d, and Id2, normally elevated
upon an LMPP’s restriction into a GMP may result from such
a network imbalance. Thus, Ikaros is a key coordinator in
a lympho-myeloid genetic network that balances development
of the innate and adaptive immune systems at the earliest
steps of hematopoiesis. Loss of Ikaros does not deregulateexpression of nuclear factors that have been previously reported
to control lymphocyte development at its earliest stages, such as
PU.1 and E2A (Dias et al., 2008; Nutt and Kee, 2007).
Ikaros also regulates a series of genetic events that contribute
to antigen-receptor rearrangement. As shown here, sterile tran-
scripts from the Igh locus and the end-nucleotide addition
enzyme,Dntt, are in the first wave of lymphoid-lineage transcrip-
tional priming activated in the HSC, propagated in the LMPP,
and dependent on Ikaros for expression. Priming of sterile tran-
scripts from the Igk locus and IgJ occurs downstream of the HSC
within the LMPP and is also dependent on Ikaros. Although
expression of these genes does not influence lymphoid potential
at this early stage, their deregulation suggests a role for Ikaros at
subsequent stages of lymphoid development.
Notably, of the genes that are negatively regulated by Ikaros,
a significant fraction consists of HSC-affiliated genes. Several
of these have been implicated in self-renewal. The failure to
extinguish stem cell transcripts such as Tie1, Tie2, and Mpl
may result in an abnormal acquisition of stem cell features in
Ikaros-deficient lympho-myeloid progenitors. A similar dere-
pression of stem cell-specific genes was recently reported in
human B cell precursor acute lymphoblastic leukemias in which
the Ikaros gene has been mutated, possibly contributing to poor
clinical outcomes after chemotherapy (Georgopoulos, 2009;
Mullighan et al., 2009). An increase in early erythroid-lineage
genes was also observed (Gata1, Klf9, Gja1); however, this did
not appear to have an overt effect on the mutant LMPP’s differ-
entiation toward the erythroid pathway (Yoshida et al., 2006). The
pre-established expression of myeloid factors in the mutant
progenitor may readily overcome this gene expression effect.
Future studies on these Ikaros-based genetic and epigenetic
networks in operation at the earliest stages of hematopoiesis
will provide us with new means of manipulating self-renewal
and the choice of cell fate during normal and aberrant manifes-
tations of hematopoiesis, with important implications for both
basic and clinical research.
EXPERIMENTAL PROCEDURES
Mice
Transgenic mice and Ikaros-null mice were bred andmaintained at theMassa-
chusetts General Hospital animal facility and were 4–12 weeks when analyzed.
Intrathymic Injections and Analysis
Congenic recipient mice (CD45.1) were sublethally irradiated and injected
intrathymically with 13 103 of LKGFPhi (GMP) or 25 of LSKGFP+ (LMPP) cells.
Thymi were harvested 6 or 21 days after injection and analyzed as described in
the Supplemental Data.
Intravenous Injections and Analysis
Recipient mice (C57BL/6) were sublethally irradiated and injected intrave-
nously with 2000 of LSK GFP+ (LMPP), 7500 of LK GFPhi (GMPa), or 30,000
of LK GFPhi (GMPb) cells sorted from the Ikaros-GFP reporter transgenic
line, along with 2 3 105 BM cells of host origin. Donor contribution to various
hematopoietic lineages in the bone marrow and thymus was tested from 5 to
22 days after injection, with the use of GFP as a donor marker.
Antibodies
Antibodies utilized in these studies are described in the Supplemental Data.
Flow Cytometry and Cell Sorting
Bone marrow cells were isolated and immunolabeled as described in the
Supplemental Data.
Immunity
Regulation of Lymphoid Potential from HSC to GMPMicroarray, Bioinformatics, and Statistical Analyses
LSK GFP/lo (HSC), LSK GFP+ (LMPP), LK GFP (MEP), LK GFPhi (GMP), and
proB populations were isolated from WT or Ikaros-null B-p-GFP-C mice as
described in the Supplemental Data. RNA isolation, aRNA probe synthesis,
microarray chip hybridization, data normalization, and various bioinformatics
and statistical analyses performed are described in Yoshida et al., 2008 and
in the Supplemental Data. Data from microarray analysis are available through
the Gene Ontology (GO) public database (http://www.geneontology.org/).
Multiplex Single-Cell RT-PCR Analysis
Single cells were sorted into 96-well plates for cDNA synthesis and multiplex
RT-PCR analyses as described in the Supplemental Data.
Single-Cell and Limiting Dilution Analysis of Progenitors
Cells were sorted onto 96-well plates with OP9 and OP9-DL1 cells (Schmitt
and Zuniga-Pflucker, 2002) for limiting dilution assays and propagated as
described in (Yoshida et al., 2006). Cultures were checked for growth on
days 8–11 (OP9) or days 18–21 (OP9-DL1). Wells with >30 hematopoietic cells
were scored as positive, and their lineage identity was tested by FACS.
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The GO database accession number for the microarray data reported in this
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